Documents
Subunit analysis of Monoclonal Antibodies using bioZen™ 3.6 µm Intact XB-C8 (TN-1253)
Impurity profiling and characterization of intact biological subunits presents many challenges because of a need to identify small differences between variants. bioZen 3.6 µm Intact XB-C8 and C4 are packed with highly specialized wide pore core-shell particles which provide narrower, taller peaks for biomolecules resulting in a greater resolving power when analysing the target HC/LC, Fc/Fab or isoforms. In this technote we look at the separation of scFc and F(ab’)2 fragment separations of cetuximab through an IdeS digestion and heavy chain/light chain analysis through a DTT reduction of rituximab. We then compare the bioZen Intact XB-C8 to another market leading column used for similar applications.
Subunit analysis of Monoclonal Antibodies using bioZen™ 3.6 µm Intact XB-C8 (TN-1253)
Impurity profiling and characterization of intact biological subunits presents many challenges because of a need to identify small differences between variants. bioZen 3.6 µm Intact XB-C8 and C4 are packed with highly specialized wide pore core-shell particles which provide narrower, taller peaks for biomolecules resulting in a greater resolving power when analysing the target HC/LC, Fc/Fab or isoforms. In this technote we look at the separation of scFc and F(ab’)2 fragment separations of cetuximab through an IdeS digestion and heavy chain/light chain analysis through a DTT reduction of rituximab. We then compare the bioZen Intact XB-C8 to another market leading column used for similar applications.
Document Type:
Technical Notes
Separation Modes:
Reversed Phase